The aggregate gross proceeds to Benitec from the underwritten offering and the concurrent registered direct offering are expected to be approximately $30 million, prior to deducting underwriting ...

Research analysts at Leerink Partnrs dropped their FY2028 EPS estimates for ARS Pharmaceuticals in a research note issued to ...

Leerink Partners initiated coverage on shares of Medpace (NASDAQ:MEDP – Free Report) in a research note released on Monday morning, Marketbeat.com reports. The brokerage issued a market perform rating ...

CVS Health saw a notable shift as Tocqueville Asset Management slashed its stake in the company by over 50% in Q4. Other ...

Fintel reports that on March 24, 2025, Leerink Partners initiated coverage of Medpace Holdings (NasdaqGS:MEDP) with a Market ...

Leerink analyst Michael Cherny initiated coverage of Medpace (MEDP) with a Market Perform rating and $330 price target The firm notes Medpace ...

Fintel reports that on March 21, 2025, Leerink Partners downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from ...

Thank you very much for joining us for the next session at the Leerink Global Healthcare Conference. I'm Marc Goodman, one of the biopharma analyst, and we're lucky to have Biogen with us here ...

For those of you who don't know me, my name is Dave Risinger. I'm responsible for diversified biopharma research at Leerink Partners. It's very much my pleasure to welcome members of Lilly's ...

On Monday, 10 March 2025, Abeona Therapeutics (NASDAQ: ABEO) presented at Leerink’s Global Healthcare Conference 2025, outlining its strategic plans for the commercial launch of PZcell.

On Monday, 10 March 2025, Amicus Therapeutics (NASDAQ: FOLD) presented at Leerink’s Global Healthcare Conference 2025. The company showcased its strategic focus on achieving profitability and ...